GCG and type 2 diabetes mellitus: The observation of GLP-1 agonist’s impact on cardiovascular outcomes is particularly significant given the diverse galaxy of existing anti-diabetic medications and the need to identify therapies that not only manage glycemic control but also manage the increased T2DM-associated cardiovascular risks.